Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With or Without Ipilimumab or Cabozantinib in Advanced Hepatocellular Carcinoma
jRCT2080222889Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of nivolumab in hepatocellular carcinoma (HCC) (4 arms), sponsored by Bristol Myers Squibb. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080222889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222889.